Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

计划入组 14 人 · 首次发布于 2021 年 9 月 23 日

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

计划入组 120 人 · 首次发布于 2018 年 7 月 9 日

Pharmacodynamic Study of BKM120 in Breast Cancer

计划入组 20 人 · 首次发布于 2012 年 1 月 20 日

PI3K/Akt/mTOR inhibitors (Endo/Jubilant Biosys)

PI3K/mTOR Inhibitor 8o

dual PI3K/mTOR inhibitors (cancer)

PINK PEARLS INC

United States

Teeter Motor Company

United States

TOYOTA MOTOR CORPORATION

Japan

Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR

Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results

Advanced Endometrial Cancer Pipeline Gains Momentum as ADCs, Immunotherapy and Targeted Combinations Reshape Treatment